Heparin: Usage, Dosing, and Management [Unfractionated Heparin (UFH), Low Molecular Weight Heparin (LMWH / Enoxaparin)]

A table for the Dosage and Administration of Heparin:

Key Notes:

1. Adjustment of Doses: Based on aPTT monitoring.
   • If aPTT is below target, increase the infusion rate by 10-20%.
   • If aPTT is above target, decrease the infusion rate by 10-20% or stop for 1 hour and restart at a lower rate.
2. When to Monitor:
   • aPTT should be measured 6 hours after the start of the infusion and after every dose adjustment. Once the therapeutic range is achieved, less frequent monitoring is required (e.g., every 24 hours).
3. Reversal of Heparin: In case of overdose or major bleeding, Protamine sulfate can be administered:
   • 1 mg of protamine neutralizes 100 units of Heparin administered in the last 2-3 hours (max dose of 50 mg).

---

1. Introduction to Heparin

Heparin is an anticoagulant medication widely used in both therapeutic and prophylactic settings to prevent and treat thrombosis. It works by inhibiting thrombin and other clotting factors in the coagulation cascade, specifically by enhancing the activity of antithrombin III. There are two primary forms of Heparin used in clinical practice:

• Unfractionated Heparin (UFH)
• Low Molecular Weight Heparin (LMWH) (such as Enoxaparin), though the focus here will be on UFH.

UFH is administered via intravenous (IV) or subcutaneous routes and requires close monitoring due to its variable bioavailability and risk of bleeding.

---

2. Indications for Heparin Use

Heparin is indicated for a range of conditions that involve abnormal blood clot formation, including:

1. Deep Vein Thrombosis (DVT)
2. Pulmonary Embolism (PE)
3. Acute Coronary Syndrome (ACS) (e.g., myocardial infarction)
4. Atrial Fibrillation with a risk of embolism
5. Venous thromboembolism (VTE) prophylaxis in at-risk hospitalized patients
6. Cardiopulmonary bypass surgeries or extracorporeal life support (ECLS/ECMO)
7. Stroke prevention in specific populations (e.g., atrial fibrillation patients)

---

3. Criteria for Heparin Use

• Acute conditions requiring immediate anticoagulation: Heparin is typically the first choice when rapid anticoagulation is needed due to its fast onset of action.
• Bridging therapy: It is often used as a bridge when transitioning to or from warfarin, especially when immediate anticoagulation is required (e.g., perioperative periods).
• Renal impairment: In patients with significant renal impairment, UFH may be preferred over LMWH, which is primarily renally cleared.
• Patients requiring close monitoring: Due to the reversibility of its effects and the short half-life, UFH is preferred when titratable anticoagulation is needed, such as in patients with a high bleeding risk or those undergoing procedures.

---

4. Dosage and Administration of Heparin

Heparin dosing varies according to the clinical situation, patient’s weight, and whether it is being used for treatment or prophylaxis.

4.1. Treatment Dosing (Intravenous UFH)

In acute conditions like DVT, PE, or ACS, Heparin is typically administered as a bolus followed by a continuous infusion.

Standard Regimen:

• Loading Dose (Bolus): 60-80 units/kg IV (maximum 5000 units)
• Maintenance Infusion: 12-15 units/kg/hour IV, adjusted based on activated Partial Thromboplastin Time (aPTT) monitoring (Target: aPTT 1.5 to 2.5 times control value)

Example (for a 70 kg patient):

• Bolus: 70 kg x 80 units/kg = 5600 units (round to 5000 units)
• Infusion: 70 kg x 15 units/kg/hour = 1050 units/hour (typically round to 1000 units/hour)

Monitoring: After initiation, aPTT should be measured 6 hours post-infusion and doses should be adjusted according to hospital-specific protocols.

4.2. Prophylactic Dosing (Subcutaneous UFH)

For VTE prophylaxis in non-surgical and post-operative patients:

• Standard prophylactic dose: 5000 units subcutaneously every 8-12 hours.

This regimen is commonly used in immobilized patients (e.g., post-surgery or those admitted for heart failure or respiratory failure) to prevent clot formation.

4.3. Adjustments Based on aPTT

If the patient’s aPTT is:

• Below target range: Increase infusion rate by 10-20%.
• Above target range: Decrease infusion rate by 10-20% or pause for 1 hour and restart at a lower rate.

4.4. Renal Function Considerations

Although UFH is not significantly renally cleared, careful monitoring is required in patients with renal impairment due to the increased risk of bleeding, particularly when LMWH or other anticoagulants are not appropriate.

---

5. Management of Heparin Therapy

5.1. Monitoring and Adjustments

The effectiveness and safety of Heparin are closely monitored using aPTT levels, typically measured 6 hours after starting therapy and then at regular intervals. The goal is to maintain a therapeutic aPTT range of 1.5 to 2.5 times the control value. In critically ill patients or those undergoing procedures, more frequent monitoring may be necessary.

Other Monitoring Parameters:

• Complete Blood Count (CBC): Monitor platelet levels for Heparin-induced thrombocytopenia (HIT).
• Signs of Bleeding: Monitor for signs of overt bleeding, including hematuria, gastrointestinal bleeding (melena), hemoptysis, or retroperitoneal hemorrhage.

5.2. Complications and Side Effects

1. Bleeding: The most common complication. Signs of excessive bleeding include easy bruising, prolonged bleeding from cuts, blood in urine or stool, and unexplained nosebleeds.
   • Management: If significant bleeding occurs, stop the Heparin infusion and consider administering protamine sulfate, a specific antidote for Heparin. The dose of protamine is based on the amount of Heparin given in the previous 2-3 hours (1 mg of protamine neutralizes 100 units of Heparin).
2. Heparin-Induced Thrombocytopenia (HIT): A rare but serious immune-mediated complication where antibodies form against Heparin-platelet factor 4 complexes.
   • Management: If HIT is suspected (platelet count decreases by more than 50% or absolute platelet count drops to <150,000/microL), Heparin must be discontinued immediately and alternative anticoagulation (e.g., argatroban or fondaparinux) should be initiated.

5.3. Reversal of Heparin

In cases of Heparin overdose or severe bleeding, protamine sulfate is used to neutralize Heparin’s anticoagulant effects. The typical dosage is:

• 1 mg protamine per 100 units of Heparin administered in the last 2-3 hours (maximum dose of 50 mg). Protamine sulfate should be given intravenously slowly to avoid adverse reactions.

5.4. Transitioning to Long-Term Anticoagulation

Once the patient’s condition is stabilized, long-term anticoagulation may be initiated. Heparin is commonly used as a bridge to oral anticoagulants like warfarin or direct oral anticoagulants (DOACs) (e.g., apixaban, rivaroxaban).

• For warfarin, Heparin is continued until the international normalized ratio (INR) is within the therapeutic range (typically 2.0-3.0), then gradually discontinued.
• For DOACs, the transition occurs once therapeutic levels are achieved, with Heparin being stopped shortly after the initiation of the oral agent.

---

6. Special Considerations

6.1. Heparin in Pregnancy

• Heparin (UFH and LMWH) does not cross the placenta and is considered safe for use in pregnant women.
• Dosing in pregnancy may require adjustments due to changes in plasma volume and renal clearance.
• LMWH is often preferred due to its lower risk of HIT and easier dosing, but UFH may still be used, particularly in cases where frequent monitoring and adjustability are required.

6.2. Contraindications

• Active major bleeding
• Severe thrombocytopenia (HIT)
• Recent hemorrhagic stroke
• Uncontrolled hypertension
• Known hypersensitivity to Heparin

6.3. Perioperative Use of Heparin

In surgical patients, Heparin may be used before and after surgery to reduce the risk of thromboembolism. Preoperative Heparin is often stopped 4-6 hours before surgery and resumed postoperatively once bleeding risk is controlled.

---

7. Summary and Clinical Pearls

• Initial loading dose: 60-80 units/kg (max 5000 units), followed by continuous infusion at 12-15 units/kg/hour, titrated to maintain aPTT at 1.5-2.5 times the control.
• Close monitoring is crucial, particularly aPTT and platelet count (for HIT).
• Bleeding is the primary adverse effect, and protamine sulfate can be used for reversal in cases of overdose or major bleeding.
• Heparin-induced thrombocytopenia requires immediate discontinuation of Heparin and initiation of alternative anticoagulation.
• Transition from Heparin to long-term anticoagulation (e.g., warfarin or DOAC) is based on clinical condition and INR or DOAC levels.

This comprehensive guide provides a thorough understanding of Heparin's usage, dosing, and management, including complications and transitions to other anticoagulants.